Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: Instagram
V, a member of K-pop sensation BTS, has revealed that he has been dealing with hearing loss in one ear for about two and a half years.
V, whose real name is Kim Tae-hyung, opened up about the condition for the first time during a livestream amid the band's highly anticipated world tour.
"If the hearing in my left ear is at 100, it's only about 30 in my right," V said.
The 30-year-old singer said his hearing became worse while he was serving in the military. However, he initially ignored the problem, believing it was "a matter of mental strength," BBC reported.
He said he is now taking medication and visiting the hospital regularly.
V also admitted to pushing through pain during BTS' current tour, revealing that he is dangerously close to developing a stress fracture in his leg.
“My shin is right at the point just before a stress fracture. Even today on stage, my heart was set on running around, but it hurt too much at points and I couldn’t," he was quoted as saying by Channel News Asia.
Doctors have warned him about inflammation and early bone damage.
“It hasn’t reached a stress fracture yet, but there’s a lot of inflammation in my shin, and I think there’s some microdamage to the bone. I’ll be careful with myself so I can finish this tour properly,” he added.
BTS is currently halfway through its massive Arirang world tour, which will stop in Singapore in December and conclude in the Philippines in March 2027.
Hearing loss can happen when any part of the ear is not working in the usual way. This includes:
Hearing loss is a growing health concern worldwide. According to the WHO, more than 1.5 billion people—nearly 20% of the world's population—live with some degree of hearing loss. Of these, approximately 430 million people have disabling hearing loss requiring rehabilitation.
Hearing loss can have a significant impact on a person's life, affecting education and job prospects.
Hearing loss can occur at any time during life. Causes can range from genetic factors to conditions such as Down syndrome or Usher syndrome.
Other factors include:
To help prevent hearing loss in adults:
Credit: X.Com
Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.
The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.
“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.
Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.
Possible warning signs include:
Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.
A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.
Doctors may recommend coronary angiography for:
Regular checkups can help detect heart disease early and monitor risk factors such as:
Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.
Regular heart checkups are particularly important for people who:
Depending on individual risk factors, a heart checkup may include:
Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.
Credit: iStock
Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.
The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.
Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.
Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.
Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.
The reported deaths included:
The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.
The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.
Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.
NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.
GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.
“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.
The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.
Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.
In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.
However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.
© 2024 Bennett, Coleman & Company Limited